Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

Publication ,  Journal Article
Diez-Perez, A; Naylor, KE; Abrahamsen, B; Agnusdei, D; Brandi, ML; Cooper, C; Dennison, E; Eriksen, EF; Gold, DT; Guañabens, N; Hadji, P ...
Published in: Osteoporos Int
March 2017

UNLABELLED: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. INTRODUCTION: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. METHODS: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. RESULTS: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. CONCLUSIONS: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Osteoporos Int

DOI

EISSN

1433-2965

Publication Date

March 2017

Volume

28

Issue

3

Start / End Page

767 / 774

Location

England

Related Subject Headings

  • Procollagen
  • Peptides
  • Peptide Fragments
  • Osteoporosis, Postmenopausal
  • Medication Adherence
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Drug Evaluation, Preclinical
  • Diphosphonates
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Diez-Perez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C., … Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society, . (2017). International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int, 28(3), 767–774. https://doi.org/10.1007/s00198-017-3906-6
Diez-Perez, A., K. E. Naylor, B. Abrahamsen, D. Agnusdei, M. L. Brandi, C. Cooper, E. Dennison, et al. “International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.Osteoporos Int 28, no. 3 (March 2017): 767–74. https://doi.org/10.1007/s00198-017-3906-6.
Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 Mar;28(3):767–74.
Diez-Perez, A., et al. “International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.Osteoporos Int, vol. 28, no. 3, Mar. 2017, pp. 767–74. Pubmed, doi:10.1007/s00198-017-3906-6.
Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, Gold DT, Guañabens N, Hadji P, Hiligsmann M, Horne R, Josse R, Kanis JA, Obermayer-Pietsch B, Prieto-Alhambra D, Reginster J-Y, Rizzoli R, Silverman S, Zillikens MC, Eastell R, Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 Mar;28(3):767–774.
Journal cover image

Published In

Osteoporos Int

DOI

EISSN

1433-2965

Publication Date

March 2017

Volume

28

Issue

3

Start / End Page

767 / 774

Location

England

Related Subject Headings

  • Procollagen
  • Peptides
  • Peptide Fragments
  • Osteoporosis, Postmenopausal
  • Medication Adherence
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Drug Evaluation, Preclinical
  • Diphosphonates